Longboard Pharmaceuticals, Inc.

4275 Executive Square, Suite 950 La Jolla, California 92037

October 5, 2022

VIA EDGAR

Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Jimmy McNamara

RE: Longboard Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed September 30, 2022 File No. 333-267674

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective at 4:30 p.m. Eastern Time on October 11, 2022, or as soon thereafter as is practicable.

Thank you for your assistance. If you should have any questions, please contact Alexa Ekman of Cooley LLP, counsel to the registrant, at (858) 550-6183.

LONGBOARD PHARMACEUTICALS, INC.

By: /s/ Brandi L. Roberts
Brandi L. Roberts
Chief Financial Officer